Table 2 Treatment characteristics of included trials

Gordon AC

REMAP-CAP

Tocilizumab: 8 mg/kg IV (max 800 mg); second dose 12–24 h at physician discretion; Sarilumab: 400 mg IV, one dose

N/A

N/A

100.0

29.0

90.7

Respiratory and cardiovascular organ support-free days up to day 21

Hospital stay

Hermine O

CORIMUNO-TOCI 1

8 mg/kg IV (max 800 mg); second dose 400 mg on day 3 at discretion of attending physician

N/A

10

0.0

0.0

47.7

Death or NIMV/IMV day 4 (WHO-CPS > 5); survival without MV on day 14

Hospital stay

Lescure FX

N/A

400 mg IV or 200 mg IV. Second dose based on clinician’s discretion within 24–48 h

N/A

5

35.6

11.6

42.1

Time to clinical improvement

60 days

RECOVERY Collaborative Group

RECOVERY

800 mg if weight > 90 kg; 600 mg if weight > 65 and ≤ 90 kg; 400 mg if weight > 40 and ≤ 65 kg; and 8 mg/kg if weight ≤ 40 kg. A second dose could be given, according to the clinician opinion, if patient’s condition did not improve

N/A

9 (tocilizumab) vs 10 (standard care)

N/A

13.7

82.2

28-day mortality

28 days

Rosas IO

COVACTA

8 mg/kg IV (max 800 mg); second dose 8–24 h after if no improvement/worsening

N/A

11 (tocilizumab) vs 10 (placebo)

56.4

37.7

42.2

Clinical status on 7-category ordinal scale at day 28

28 days

Rutgers A

PreToVid

8 mg/kg IV (max 800 mg); second dose 8 h after if hypoxia not resolved

N/A

9 (tocilizumab) vs 9 (standard care)

N/A

N/A

88.4

30-day mortality

30 days

Salama C

EMPACTA

8 mg/kg IV (max 800 mg); second dose 8–24 h after if no improvement/worsening

N/A

8

15.4

0.0

82.8

Death or IMV/ECMO by day 28

60 days

Salvarani C

RCT-TCZ-COVID-19

8 mg/kg IV (max 800 mg), 2 doses 12 h apart

N/A

8

0.0

0.0

10.6

Clinical worsening within 14 days

Hospital stay

Sivapalasingam S

N/A

200 mg IV, 400 mg IV, or 800 mg IV

N/A

N/A

N/A

N/A

29.0

CRP levels (Phase 2); Clinical improvement in patients receiving MV at baseline (Phase 3)

29 days

Soin AS

COVINTOC

6 mg/kg IV (max 480 mg); second dose 12 h–7d after if no improvement/worsening

N/A

N/A

65.9

5.0

91.1

Disease progression (from moderate to severe or from severe to death) within 14 days

Hospital stay

Stone JH

BACC Bay Tocilizumab Trial

8 mg/kg IV (max 800 mg)

N/A

9

4.1

0.0

11.6

Death or IMV by day 28

28 days

Talaschian M

N/A

8 mg/kg IV (max 800 mg)

N/A

N/A

0.0

0.0

33.3

28-day mortality

28 days

Veiga VC

TOCIBRAS

8 mg/kg IV (max 800 mg)

N/A

10

N/A

16.3

86.0

Clinical status at day 15 (seven-level ordinal scale)

29 days

Wang D

N/A

400 mg IV; second dose 24 h if still fever

N/A

23

N/A

0.0

N/A

Cure rate of enrolled patients

Hospital stay

Zhao H

N/A

4–8 mg/kg IV; second dose 24 h if still fever

1600 mg × 2 p.p. day 1; 600 mg × 2 p.o. day 2–7

N/A

N/A

0.0

N/A

Cumulative lung lesion remission rate (lung CT examination indicated absorption of lung inflammation)

Hospital stay